Lyme disease history | Patients with persistent symptoms following treated Lyme disease (N = 12) |
---|---|
Medical record-confirmed Lyme disease presentation | |
CDC confirmed: physician-documented erythema migrans rasha | 6 (50.0%) |
CDC probable: subjective symptoms/(+) serologyb | 6 (50.0%) |
PTLDS symptom duration ≥ 6 months at study visit | 8 (66.7%) |
Self-reported cognitive symptoms | |
Memory change, moderate or severe | 7 (58.3%) |
Difficulty finding words, moderate or severe | 7 (58.3%) |
Difficulty focusing or concentrating, moderate or severe | 9 (75.0%) |
Cognitive symptoms,c any | 12 (100.0%) |
Neurocognitive test T-scores | |
Trail making test [28], part A | 52.50 ± 18.53 (17.00, 80.00) |
Trail making test, part B | 46.67 ± 14.25 (19.00, 68.00) |
HVLT [29] total recall | 48.50 ± 11.87 (32.00, 64.00) |
HVLT delayed recall | 47.92 ± 11.41 (25.00, 59.00) |
HVLT retention | 51.00 ± 9.36 (26.00, 61.00) |
HVLT recognition discrimination | 46.33 ± 12.52 (20.00, 58.00) |
WAIS-IV [30] digit span | 49.25 ± 8.28 (37.00, 67.00) |
WAIS-IV coding | 52.83 ± 7.72 (40.00, 70.00) |
ACT [31] 9d | 54.10 ± 7.26 (37.00, 62.00) |
ACT 18d | 54.50 ± 8.83 (38.00, 69.00) |
ACT 36d | 55.60 ± 9.92 (37.00, 69.00) |
Standardized symptom questionnaires | |
Fatigue Severity Scale Total Score | 50.42 ± 10.33 (25.00, 63.00) |
Pittsburgh Sleep Quality Index Total Score | 11.40 ± 4.67 (4.00, 19.00) |
Short-Form McGill Pain Questionnaire Total Score | 11.67 ± 6.84 (0.00, 24.00) |
Beck Depression Inventory II Total Score | 14.18 ± 7.10 (3.00, 24.00) |
SF-36 Physical Component Score | 34.91 ± 8.24 (20.21, 50.06) |
SF-36 Mental Component Score | 38.60 ± 11.95 (20.86, 59.47) |